← FDA DRUG APPROVALS

FDA ANDA · ANDA091244

TESTOSTERONE CYPIONATE

Sponsor: HIKMA FARMACEUTICA

APPLICATION
ANDA091244
TYPE
ANDA
ORIGINAL APPROVAL
2012-05-01
LATEST ACTION
2025-07-11
ROUTE
INTRAMUSCULAR, INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Prescription

Products

TESTOSTERONE CYPIONATEPrescription
TESTOSTERONE CYPIONATE 200MG/ML · INJECTABLE · INJECTION

Approval history

2025-07-11Labeling · Supplement 23 · standardAP
2025-07-09Labeling · Supplement 12 · standardAP
2025-07-09Labeling · Supplement 13 · standardAP
2017-03-27Labeling · Supplement 7 · standardAP
2016-07-26Supplement · Supplement 2AP
2015-07-22Labeling · Supplement 6 · standardAP
2015-05-11Labeling · Supplement 5 · standardAP
2014-06-19Labeling · Supplement 4 · standardAP
2012-05-01OriginalReviewAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →